Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer

Phase 1/2 Completed 30 enrolled Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy in treating patients with metastatic or locally advanced bladder cancer.

Timeline

Start: 1997-09
Primary completion: 2004-08
Completion: 2004-08

Publications

Results Milowsky MI, Nanus DM, Maluf FC, Mironov S, Shi W, Iasonos A, Riches J, Regazzi A, Bajorin DF. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Oncol. 2009 Sep 1;27(25):4062-7. doi: 10.1200/JCO.2008.21.2241. Epub 2009 Jul 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	—	Intravenous
Subject	Doxorubicin	Other / unclassified	—	Intravenous
Subject	Gemcitabine	Small molecule	—	Intravenous
Subject	Ifosfamide	Small molecule	—	Intravenous
Subject	Paclitaxel	Small molecule	—	Intravenous
Background	filgrastim	Protein / enzyme biologic	—	Subcutaneous

Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer

Summary

Timeline

Publications

Drugs

Indications